BOPA 2017 | The impact of novel NSCLC immunotherapies

The landscape of NSCLC treatment is evolving rapidly. In this interview, Yvonne Summers, BSc, MB ChB, MSc, PhD, FRCP from The Christie NHS Foundation Trust, Manchester, UK, discusses exciting novel immunotherapies for NSCLC, including PD-1-targeting biologics such as pembrolizumab. Dr Summers explains the impacts of these new treatments on the clinical management of patients, including the tests required prior to commencing therapy. This video was recorded at the British Oncology Pharmacy Association (BOPA) 20th Annual Symposium 2017 in Glasgow, UK.